{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(6)"],"submitter":["Lu J"],"pubmed_abstract":["<h4>Objective</h4>Sarcomas are a group of rare malignancies with various subtypes. Patients with metastatic sarcoma who have failed traditional treatments can possibly achieve better prognoses from using novel therapies, including anti-programmed death-1 (PD-1)-based therapies.<h4>Methods</h4>We retrospectively analyzed clinical data of 24 metastatic sarcoma patients from June 15, 2016 to December 30, 2019. These patients mainly received angiogenesis inhibitors combined with anti-PD-1 therapy after they became resistant to traditional treatments. Furthermore, 8 patients underwent panel DNA and whole transcript sequencing.<h4>Results</h4>Six patients received 2 cycles of anti-PD-1 therapy and were included in the safety evaluation only group. The median follow-up time was 5.77 months. The m"],"journal":["Cancer biology & medicine"],"pagination":["j.issn.2095-3941.2021.0270"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9257312"],"repository":["biostudies-literature"],"pubmed_title":["The efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma."],"pmcid":["PMC9257312"],"pubmed_authors":["Liao Z","Trent J","Yang J","Teng S","Chen K","Ren Z","Yu H","Zhao Y","Wu H","Li X","Yang Y","Li T","Lu J","Xing R","Zhao J"],"additional_accession":[]},"is_claimable":false,"name":"The efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma.","description":"<h4>Objective</h4>Sarcomas are a group of rare malignancies with various subtypes. Patients with metastatic sarcoma who have failed traditional treatments can possibly achieve better prognoses from using novel therapies, including anti-programmed death-1 (PD-1)-based therapies.<h4>Methods</h4>We retrospectively analyzed clinical data of 24 metastatic sarcoma patients from June 15, 2016 to December 30, 2019. These patients mainly received angiogenesis inhibitors combined with anti-PD-1 therapy after they became resistant to traditional treatments. Furthermore, 8 patients underwent panel DNA and whole transcript sequencing.<h4>Results</h4>Six patients received 2 cycles of anti-PD-1 therapy and were included in the safety evaluation only group. The median follow-up time was 5.77 months. The m","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-05-09T23:42:15.512Z","creation":"2025-04-04T22:12:19.204Z"},"accession":"S-EPMC9257312","cross_references":{"pubmed":["34817950"],"doi":["10.20892/j.issn.2095-3941.2021.0270"]}}